ConvaTec Group (LON:CTEC – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at UBS Group in a research report issued on Monday,Digital Look reports. They presently have a GBX 375 price target on the stock. UBS Group’s price target points to a potential upside of 78.06% from the company’s previous close.
CTEC has been the topic of several other research reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 315 price target on shares of ConvaTec Group in a report on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 315 price objective on shares of ConvaTec Group in a research note on Wednesday, April 8th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 340 target price on shares of ConvaTec Group in a research note on Tuesday, April 21st. Citigroup lowered their target price on ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating on the stock in a report on Monday. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 325 price target on shares of ConvaTec Group in a report on Friday. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of GBX 310.22.
Get Our Latest Report on ConvaTec Group
ConvaTec Group Price Performance
Insider Activity at ConvaTec Group
In other news, insider Jonny Mason sold 291,149 shares of ConvaTec Group stock in a transaction dated Monday, March 16th. The shares were sold at an average price of GBX 234, for a total transaction of £681,288.66. 0.95% of the stock is currently owned by company insiders.
About ConvaTec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Further Reading
- Five stocks we like better than ConvaTec Group
- These Stocks Could Be the Biggest Winners of the 2026 Midterms
- 3 Infrastructure Stocks Fueling the Data Center Building Boom
- Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent Stocks
- As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
